Occidental (OXY)
The desk's stance
On our research list, not on the slate.
What the company does
Permian pure-play with a carbon-capture side bet — and Warren Buffett’s favorite oil stock, with Berkshire holding ~28%.
In short: Upstream oil and gas exploration. Category: Large-cap E&P Oil Producer. Sector: Energy, Oil & Gas E&P.
G-Street Value and Score
G-Street Value: $65.84, computed Oct 18, 2026 (confidence: medium).
How we got there: 70% analyst leg $65.84 (5 analyst targets, credibility- and freshness-weighted, after 8% optimism discount) + 30% GainStreet factor value $111.1 (23.32× fwd EPS anchored to resources multiples) — capped at the analyst leg; factors never out-bull the street.
G-Street Score: 67 out of 100 (Medium).
- Top-line growth & guidance: 20 of 32
- Margin power: 15 of 15
- Revenue visibility & quality: 3 of 11
- Profitability & balance sheet: 17 of 24
- Capital allocation & governance: 3 of 6
- Valuation, sentiment & momentum: 9 of 12
Our current thesis
Updated Oct 11, 2026
The thesis
- Permian inventory depth and OxyChem divestment proceeds accelerate deleveraging toward the $10B debt target.
- Substantial Berkshire Hathaway backing provides capital structure validation and strong downside valuation support.
- Four-quarter EPS beat streak demonstrates robust cash generation and sector-leading 30% profit margins.
Risks
- Unhedged upstream production leaves corporate earnings highly exposed to global crude benchmark declines.
- Balanced 30-day EPS revisions reflect persistent uncertainty over normalized commodity pricing and strip durability.
- Geopolitical and operational disruptions can pressure quarterly international production volumes and realizations.
What we're watching
- Q3 2026 earnings release on November 9, 2026, focusing on Permian operational efficiency.
- Deleveraging progress toward the $10B net debt milestone to unlock common share buybacks.
- Crude benchmark stability above $70 to sustain quarterly free cash flow generation.
Latest
OXY trades at $60.11 after posting Q2 2026 EPS of $2.40, extending a four-quarter beat streak on surging revenue of $8.06B. Goldman Sachs upgraded shares to Buy with a $69 target in October 2026, citing enhanced recovery and $4B in cash-flow expansion initiatives. Deleveraging continues following the OxyChem sale, though balanced 30-day revisions reflect near-term oil strip uncertainty.
Key numbers
As of Oct 16, 2026: market cap $62.4B · revenue growth +53.4% year over year · gross margin 73.3% · net margin 30.3% · forward P/E 13.1 · next earnings Nov 9, 2026.
Analyst price targets
Published analyst targets we could trace to a named source.
- Goldman Sachs, Buy: $69 target (October 2026). Source: benzinga.com
- Wells Fargo, Overweight: $82 target (September 2026). Source: benzinga.com
- Evercore ISI, Outperform: $70 target (September 2026). Source: benzinga.com
- UBS, Neutral: $67 target (September 2026). Source: benzinga.com
- Barclays, Overweight: $71 target (August 2026). Source: benzinga.com
On the Gainz Lab maps
Who it does business with
- Occidental supplies The Global Economy — Permian crude (about $27.0B a year). Shale barrels plus a moonshot in direct air capture.
In the Daily Brief
Named in 1 edition on 1 day.
- Aug 10, 2026: Oil surged on Hormuz jitters, and our portfolio's tech darlings are feeling the weight of profit-taking